FDA advisory committee recommends (10-0) approval of CTL nineteen (tisagenlecleucel) CAR-T therapy, for the treatment of relapsed or refractory (r/r) pediatric and youthful adult patients with B-cell acute lymphoblastic leukemia.-Novartis
Added
one month ago on fourteen July two thousand seventeen
Data from Pharmawand – Curated by Toby Galbraith – Date added 14 July 2017
Novartis announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL nineteen (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory (r/r) pediatric and youthful adult patients with B-cell acute lymphoblastic leukemia (ALL).
Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under fifteen years old and is the most common childhood cancer in the US. Effective treatment options for patients with r/r ALL are limited. In pediatric and youthfull adult patients with B-cell ALL that have relapsed numerous times or become refractory to treatment, the five-year disease-free survival is less than 10-30%].
The ODAC recommendation is based on review of the CTL nineteen r/r B-cell ALL development program, which includes the Novartis-led ELIANA probe (NCT02435849), the very first pediatric global CAR-T cell therapy registration trial. Findings from a US multicenter trial and a single site trial examining the safety and efficacy of CTL nineteen among pediatric and youthfull adult patients with r/r B-cell ALL also supported the recommendation and the Biologics License Application (BLA).
CTL nineteen was very first developed by the University of Pennsylvania (Penn) and uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular responses as well as persistence of CTL nineteen after it is infused into the patient, which may be associated with long-lasting remissions in patients. In 2012, Novartis and Penn entered into a global collaboration to further research, develop and commercialize CAR-T cell therapies, including CTL 019, for the investigational treatment of cancers. Children’s Hospital of Philadelphia (CHOP) was the very first institution to investigate CTL019 in the treatment of pediatric patients and led the single site trial.
Comment: This will be the very first chimeric antigen receptor T cell (CAR-T) therapy to reach the market. CTL nineteen is a living drug developed by extracting patients’ cells, re-engineering them to target CD19 to fight cancer and re-infusing them back into the patient.
Comments
You will need to login, to leave a comment.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Chronic Lymphocytic Leukaemia (CLL)
Refine your skill of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
No comments